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Emphysema is a complex immunological disease characterized by progressive and 
irreversible damage to the parenchymal lung tissue. While the cause of the disease can most 
often be attributed to habitual cigarette smoking or long-term exposure to other toxic 
substances, the underlying mechanisms of the pathogenesis are poorly understood. Of 
particular interest is why alveolar destruction continues to occur even after cessation of 
smoking. Data from human patient samples and laboratory animals have implicated a role 
for macrophages as they are a long-lived, abundant cell within the alveolar space that has 
the ability to secrete many of the damaging enzymes associated with tissue destruction. The 
importance of macrophages and their dynamics in the progression of emphysema are not, 
however, well understood. This work seeks to delineate the early myeloid cell dynamics in a 
murine elastase-induced emphysema model and to address the hypothesis that the early 
alterations in lung macrophage phenotype contribute to the progression of tissue 
destruction in this model. 
To elucidate the dynamics of macrophages, monocytes, and neutrophils in the lung, 
BALB/cJ mice were administered 3 enzymatic units of porcine pancreatic elastase and their 
lungs were analyzed via flow cytometry at various time points throughout the two-weeks 
following elastase administration. To evaluate the importance of lung macrophages during 
the acute period following elastase administration, macrophages were depletion by giving a 
total of three doses of clodronate-loaded liposomes. The effect of depletion on emphysema 
severity was determined by performing pulmonary function tests 21 days post-elastase. 
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As expected, neutrophils and monocytes infiltrated the lung during the acute 
inflammatory phase, peaked around day 2 and 4, respectively, and returned to baseline by 
day 14 post-elastase. Resident alveolar macrophages underwent an initial contraction, 
followed by a slight proliferation, and by day 14 there were marginally fewer cells than in 
the naïve lung. Interstitial macrophages on the other hand proliferated and peaked by day 4 
post-elastase and gradually declined to be somewhat elevated above baseline.  
Pulmonary function tests revealed that the depletion of macrophages worsened 
emphysema severity. This work supports the hypothesis that macrophages play a 
significant role in emphysema progression, however it does not address the mechanism of 
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Chronic obstructive pulmonary disease is a heterogeneous lung disease that 
comprises obstructive bronchitis, affecting the conducting airways, and emphysema, 
affecting the lower respiratory airways1. Emphysema, the focus of this thesis, is defined by a 
progressive and irreparable destruction of alveolar tissue, resulting in impaired lung 
function. The most common symptoms associated with COPD are dyspnea, chronic cough, 
excess sputum production, and fatigue.   
Chronic obstructive pulmonary disease poses a significant public health burden; 
over 65 million people are living with the disease worldwide and in 2012 the World Health 
Organization named COPD the third leading cause of death worldwide2. Due to the 
chronicity of the disease and its impact on the ability to perform tasks of daily living, COPD 
has one of the highest global years lost to disability3. 
Considering its significant strain on society, our progress toward understanding the 
cellular and molecular basis of this complex immunological disease is lagging.  Further, the 
limited number of available treatments only ameliorate symptoms but do nothing to abate 
the underlying disease4. In order to develop treatments that allay the continued tissue 
destruction, knowledge into the mechanisms of emphysema progression is necessary. 
The overall aim of this thesis is to contribute to the understanding of the immune 
environment in the emphysematous lung and its role in the progressive destruction of 
parenchymal tissue. Specifically, this work focuses on identifying the dynamics and role of 
macrophages in a murine model of progressive emphysema. The thesis will begin with 
background information to orient the reader to lung structure and function, 
COPD/emphysema, animal models of emphysema, the current understanding of 
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emphysema pathogenesis, and lastly the specific aims of this work. Part 1 of the results 
section will describe the dynamics of resident and recruited macrophages, monocytes, and 
neutrophils in the murine lung following elastase administration and Part 2 will detail the 
effect of resident macrophage depletion on the progression of elastase-induced emphysema. 
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Structure and function of the respiratory system 
Gross anatomy 
Oxygen is required for energy production by most tissues in the mammalian body, thus 
continuously providing cells with oxygen from the environment and removing carbon dioxide 
produced during aerobic metabolism is integral to the body’s proper functioning. This 
homeostasis is maintained by the respiratory system, comprised of the conducting airways, lungs, 
and chest wall. 
 The airways and their associated blood vessels are composed of branching structures that 
narrow and shorten as they eventually infiltrate the entire lung parenchyma5,6. Inspired air first 
passes through the upper airways including the nose or mouth, pharynx, and larynx, and then 
enters the lower airways of the lung via the tracheobronchial tree. The dichotomously branching 
airways in humans begin with the trachea (generation 0) which bifurcates into the left and right 
mainstem bronchi (1st generation) at an approximately 45⁰ angle at the carina, entering into the 
left and right lungs, respectively. In humans, there are three right lung lobes and two left lung 
lobes and in mice there are four right lung lobes and one left lung lobe. The bronchi continue to 
branch into bronchioles, respiratory bronchioles, alveolar ducts, and end as alveolar sacs, over the 
course of 23 generations in humans. Unlike humans, mice have monopodial branching, lack 
cartilage in the conducting airways beyond the mainstem bronchi, and lack respiratory 




FIGURE 1 Conducting airways and respiratory zone of human lung  Reproduced from 
Elseveier Inc. www.netterimages.com5, Copyright (2011). 
 
 In humans, the nose/mouth through the first 15 generations of branching airways 
comprise the conducting zone where the air is filtered, moistened, and heated as it is directed to 
the remaining 8 generations that comprise the acinus. Because the conducting airways are unable 
to facilitate gas exchange, they are referred to as the anatomical dead space, where the final 
portion of each inspiration remains without any change in composition6,7. The acinus begins with 
the respiratory bronchioles, containing a few evaginations or alveoli capable of gas exchange, and 
3 
 
leads to the alveolar ducts, culminating in the main respiratory zone composed of many alveolar 
sacs7,8.  
The branching pattern of the airways is mirrored by that of the pulmonary arteries with 
each bronchus or bronchiole closely associated with its respective artery or arteriole. In humans, 
the pulmonary veins travel to the left atrium peripherally to the bronchi whereas in mice, they 
follow a similar course to the bronchi. At the level of the alveoli, a dense mesh-like network of 
capillaries envelopes each alveolar sac, creating an environment conducive to efficient gas 
exchange. Blood in the capillary network is separated from inspired air by a thin tissue membrane 
of capillary endothelium and alveolar epithelium, just 0.6 μM thick in humans or 1/13th the 
diameter of an erythrocyte. Additionally, capillary beds are sandwiched between alveolar saccules 
and thus surrounded by air on both sides, further facilitating the exchange of oxygen in the air for 
carbon dioxide in the blood9. 
In order to ensure that this exchange is efficient as possible, the alveoli must be structured 
to achieve an extremely large surface area with an appropriately thin barrier between the alveolar 
air and capillary blood. Adult human lungs contain around 480 million alveoli10 resulting in an 
internal surface area of 24-81 m2, varying by height of the individual11–13 
Cellular environment 
 Whereas the capillary endothelium consists of a uniform layer of squamous cells, the 
alveolar membrane wall is a mosaic of two distinct types of alveolar epithelial cells or 
pneumocytes. Each of the 400 million or so alveoli in the human lung are comprised of about 40 
type I cells and 77 type II cells. Though type I cells account for only 34% of epithelial cells in the 
membrane, they are an impressive form of squamous cell that manage to cover over 95% of the 
surface.  Each type I cell covers a surface area of 5,100 μm2 via multiple large cytoplasmic 


















FIGURE 2 Mammalian alveolus  Reproduced from Elsevier Inc. www.netterimages.com5, 
Copyright (2011). 
 
 Interspersed among type I cells are the cuboidal type II cells, representing approximately 
66% of alveolar epithelial cells and covering just 5% of the alveolar surface area15. They are 
distinct from type I cells given their many phospholipid-rich lamellar bodies and apical microvilli 
that secrete interstitial fluid. While type I cells give rise to the alveolar membrane’s facilitation of 
gas exchange, type II cells maintain and protect the alveolar environment. They prevent atelectasis 
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through the release of surfactants, replace damaged epithelium through self-renewal and 
transdifferentiation, avoid alveolar edema through transepithelial sodium transport, and limit 
inflammation and microorganisms through the release of anti-inflammatory and anti-microbial 
substances such as surfactant protein-A and lysozyme15,16.  
 To maintain the basement membrane of the epithelium, underlying fibroblasts produce 
extracellular matrix components including collagen and elastin fibers, fibronectin fibrils, and 
proteoglycans17,18. Additionally, the alveolar space contains specialized immune cells including 
alveolar macrophages and a small number of lymphocytes19 (Figure 3). These cells partake in 
both the innate and adaptive immune systems and alter their phenotype from baseline in the 







FIGURE 3 Leukocytes in the respiratory zone of the lung  Reproduced from Macmillan 
Publishers Ltd: Nature Reviews Immunology19, Copyright (2014). 
 
Lung macrophages 
 The lung contains at least three distinct macrophage subsets: bronchial macrophages in 
the conducting airway, alveolar macrophages in the respiratory airway, and interstitial 
macrophages in the interstitial space between the alveolar epithelium and capillary endothelium. 
Pulmonary macrophages act to eliminate debris, apoptotic cells, and microorganisms from the 
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lung and play significant roles in the promotion and suppression of inflammation as well as wound 
healing and airway remodeling19,20. 
 Up until recently, the paradigm for the origin of tissue resident macrophages was that they 
were part of a unified mononuclear phagocyte system (MPS) that was maintained at steady-state 
by circulating monocytes that differentiate into tissue-specific macrophages.  However, cellular 
fate mapping experiments have demonstrated that these tissue resident macrophages are partially 
to not-at-all of hematopoietic or monocytic origin21,22. Further, the observation that tissue 
macrophages appear during embryogenesis prior to the appearance of monocytes creates a 
temporal challenge to the MPS paradigm22,23. From 2010 until the present, several groups 
determined that resident tissue macrophages including microglia in the brain, Langerhans cells in 
the skin, Kupffer cells in the liver, and peritoneal, kidney, and splenic macrophages were not of 
adult hematopoietic origin and were likely derived from the fetal yolk sack. In 2013, Guilliams et 
al. delineated the alveolar macrophage origin to be of Ly6Chi, CD11bhi fetal monocytes that 
colonize the developing lung at day E16.5 and subsequently begin differentiating into alveolar 
macrophages around E18.5, during the saccular stage of lung development24. Maturation of these 
cells occurs within 3 days of birth and the entire process is largely dependent on granulocyte 
macrophage-colony stimulating factor (GM-CSF). This population, comprising 90-95% of 
leukocytes in the alveolar space, is maintained through self-renewal in steady state conditions and 
has a half-life of approximately 12-months24–26.  
Conversely, interstitial macrophages have a high turnover rate at steady-state and are 
posited to be replenished by circulating Ly6C- monocytes27. Some groups suggest that in 
circumstances where alveolar macrophages are depleted (either through infection28, experimental 
depletion, or irradiation prior to bone marrow transplant29), interstitial macrophages differentiate 
into alveolar macrophages and are replenished by blood monocytes.  Landsman and Jung reported 
that following depletion of alveolar macrophages, Ly6C- monocytes are recruited to the interstitial 
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space, differentiate into an intermediate interstitial macrophage, undergo proliferative expansion, 
and then migrate into the alveolar space30.  
As the lung is a delicate organ that relies on the patency of the airways for efficient gas 
exchange, alveolar macrophages ideally maintain the sterility of the lung while limiting 
inflammation. Because they exert such a significant presence in the lung, alveolar macrophages 
are the main orchestrator of the pulmonary immune environment and interact intimately with 
alveolar epithelial cells and T cells19,26.  They highly express many anti-inflammatory proteins 
including CD200R that binds CD200 (OX-2) expressed on type II alveolar epithelial cells, 
endothelial cells, B cells, and some T cells to inhibit macrophage responsiveness to toll-like 
receptors (TLRs) and signal-regulatory protein-α (SIRP-α) that binds surfactant proteins A and D 
to inhibit macrophage phagocytosis at baseline and can also bind CD47 to prevent inflammation 
during macrophage phagocytosis of erythrocytes31. Further, alveolar macrophages express 
various scavenger receptors that sequester damage-associated molecular pattern molecules 
(DAMPs), pathogen-associated molecular pattern molecules (PAMPs), and complement to aid in 
the clearance of pathogens. Alveolar macrophages also play a role in the adaptive immune 
response by promoting tolerance to harmless antigens via poor antigen presentation to T cells and 
a lack of costimulatory molecules. Additionally, they secrete transforming growth factor (TGF)-β, 
anti-inflammatory prostaglandins, and retinoic acid that can suppress dendritic cells from 
activating effector T cells or skew them toward the development of forkhead box P3 (FOXP3)+ 
regulatory T cells19. While alveolar macrophages suppress inflammation at steady-state, in 
response to the repeated injury that is incurred with habitual cigarette smoking or indoor burning 
of biomass fuels, alveolar macrophages seem to orchestrate a pro-inflammatory, destructive lung 
environment that results in COPD and emphysema. 
 




Chronic obstructive pulmonary disease (COPD) is characterized by irreversible 
progressive airflow limitation and is comprised of a mix of small airway disease, including chronic 
obstructive bronchiolitis and bronchitis, and destruction of parenchymal lung tissue. The most 
common symptoms of COPD include chronic worsening dyspnea, cough, and sputum production1.  
The Global Initiative for Chronic Lung Disease (GOLD), the world’s foremost authority on 
COPD, recommends spirometry as the gold standard for making a definitive COPD diagnosis and 
considers it the most objective and reliable measure of lung function in humans. The diagnostic 
test measures the post-bronchodilator forced expiratory flow in 1 second (FEV1) and the forced 
expiratory volume (FVC), following complete inspiration. Post-bronchodilator measurements are 
used to ensure that any observed airway narrowing is fixed; consistent with COPD 
pathophysiology whereas resolution of airway narrowing following bronchodilators aligns more 
closely with asthma pathophysiology. Chronic obstructive pulmonary disease is defined by an 
FEV1/FVC of <0.7 and severity is classified using FEV1 percent of predicted value (based on age, 






FEV1                                             
(% predicted)
Characteristics
0 At risk >0.7 ≥80%
Normal spirometry, chronic symptoms (productive 
cough)
I Mild <0.7 ≥80% With or without symptoms
II Moderate <0.7 50-80% Symptoms progress, often include dyspnea on exertion
III Severe <0.7 30-50%
Symptoms worsen to limit activities of daily living; 
exacerbations occur
IV Very severe <0.7 <30% or <50% plus 
chronic respiratory 
failure
Very poor quality of life; exacerbations may be life-
threatening




 The focus of this thesis research will be on emphysema, a component of COPD that 
primarily manifests in patients with GOLD stage III and IV and is defined by progressive and 
irremediable loss of parenchymal lung tissue.  The destruction of this tissue, including alveolar 
epithelium, capillary endothelium, and extracellular matrix components leads to decreased 
functional surface area, capillary blood volume, elastic recoil, and increased total lung volume. 
Patients with emphysema typically present with productive cough, dyspnea, and difficulty in 
breathing and over time can develop non-respiratory symptoms including cachexia. Because 
alveolar tissue is irreversibly damaged in emphysema, there is a loss of elasticity and recoil 
capacity allowing the lung to inflate more easily per change in pressure33. This increased 
compliance of the lung allows for hyperinflation and air trapping causing the patient to exert more 
effort to expel air from the lower airways, ultimately leading to fatigue and dyspnea.  
Risk Factors  
 Chronic obstructive pulmonary disease has long been thought of as a “smoker’s disease”. 
While it is well accepted that cigarette smoking, whether active, passive, or secondary, is the most 
significant risk factor for the development of COPD, over the past decade or so, many studies in 
never-smokers have suggested other novel factors. These include indoor and outdoor pollution, 
occupational exposure to particulate matter and chemicals, poor nutrition, and early life 
conditions including frequent lower respiratory infections, asthma, maternal smoking, and low 
birth weight34–37. 
 The indoor burning of biomass for cooking and heating is an increasingly appreciated 
factor in the growing incidence of COPD. Because biomass fuels have low combustion efficiency, a 
high concentration of harmful substances including carbon monoxide, formaldehyde, and 
benzpyrene build up while burning, making this fuel source particularly injurious to the lungs. 
Throughout the world, over 3 billion people are exposed to indoor burning of biomass, the 
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majority of whom are women and children, and about half of all COPD deaths in developing 
countries are attributable to biomass smoke36.  
 In addition to environmental exposures, a small percentage of COPD cases can be 
attributed to genetic deficiencies or mutations. Approximately 1-2% of COPD patients are 
homozygous for the PiZ allele of the SERPINA1 gene which is a recessive trait primarily found in 
Northern Europe that results in serum α-1-antitrypsin (A1AT) deficiency (the primary neutrophil 
elastase inhibitor) and subsequent pulmonary emphysema38–40. 
Importantly, not all patients with A1AT deficiency go on to develop emphysema and only 
15-20% of smokers develop emphysema, underscoring the importance of genetic and 
environmental factors that play into an individual’s susceptibility to the disease41,42.  
Public health importance 
Chronic Obstructive Pulmonary Disease is associated with increased morbidity and 
mortality and poses a significant burden on society, the economy, and health resources world-
wide. Currently, over 65 million people are living with COPD and over 90% of deaths secondary to 
COPD occur in low to middle income countries. Due to the chronic and progressive nature of the 
disease, COPD accounts for over 29 million global years lost due to disability3 – one of the highest 
levels of any single disease.  In the United States, medical costs for the treatment of COPD are 
expected to reach $49 billion by 2020 and in 2010, it’s estimate that 16.4 million work days lost 
were attributable to COPD43. Due to the aging population, increasing global pollution, cigarette 
consumption in Asia, and indoor burning of fossil fuels in low and middle income countries, the 
incidence of COPD is projected to increase. In 2012, the World Health Organization ranked COPD 
as the third leading cause of death world-wide, representing 5.6% of global deaths, only after 
ischemic heart disease (13.2%) and stroke (11.9%)2.  
Despite its significant and growing public health burden, the therapy for COPD remains 
inadequate. Treatments are focused on limiting symptoms such as dyspnea and hypoxemia and 
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include the use of bronchodilators, supplemental oxygen, and glucocorticoids (effective in asthma 
but show little efficacy in COPD). While these therapies may help decrease the frequency and 
severity of exacerbations, they do nothing to limit the underlying disease processes that 
eventually lead to respiratory failure and death4. 
As a chronic disease that develops over time with habitual exposure to cigarette smoke 
and other toxic substances, the etiology of COPD and specifically emphysema, is complex. For 
example, while smoking is considered the greatest risk factor for developing emphysema, only a 
percentage of smokers end up developing the disease and a significant number of cases occur in 
never-smokers. It is clear that genetics and environmental exposures synergize to define an 
individual’s susceptibility and clinical prognosis, however, the underlying mechanisms necessary 
to develop interventions capable of halting or slowing progression, are unknown. The overarching 
purpose of this thesis work is to contribute to the understanding of the immunological 
environment in the emphysematous lung and its role in disease progression and severity. 
Animal Models of Emphysema 
The three most common experimental animal models of emphysema are genetically-
induced, cigarette smoke-induced, and protease-induced44,45.  
Certain mouse strains contain spontaneous or engineered genetic defects that result in the 
natural development of emphysema (reviewed in reference 44). For example, the Pallid mouse46 
contains a nonsense mutation in Pallidin that leads to, among other phenotypic defects, serum 
A1AT deficiency and thus progressive emphysema beginning at one month of age. Other common 
strains that spontaneously develop emphysema include the osteopetrotic mouse that lacks 
macrophage colony stimulating factor47, the tight skin mouse that has a duplication of fibrilin 148, 
and the blotchy mouse that has an X-linked copper transport defect49. Mice can also be genetically 
modified where a specific gene is either deleted or overexpressed to result in airspace 
enlargement due to alveogenesis defects, development of emphysema, or protection from the 
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development of emphysema after challenge with cigarette smoke or elastase. For example, 
deletion of surfactant protein D leads to progressive emphysema by 3 weeks of age50 and deletion 
of matrix metalloprotease (MMP)-12 has been reported to protect from cigarette smoke and 
elastase-induced emphysema51. Additionally, mice lacking the epithelial integrin αvβ6 have 
increased expression of MMP-12 and thus develop emphysema as they age. In this model, the 
emphysema phenotype is averted through loss of MMP-12 or by transgenic expression of the β6 
subunit that is involved in transforming growth factor-β (TGF- β)52. 
In 1990, Wright et al. demonstrated the first successful cigarette smoke induction of 
progressive emphysema after exposing guinea pigs to 10 unfiltered cigarettes per day, 5 days per 
week for up to a year in a smoking chamber53.  The guinea pigs developed pulmonary function 
decline and histology similar to those of COPD patients, whereas previous models in rats and 
hamsters were unable to provoke diffuse progressive emphysema. The cigarette smoke model in 
mice produces emphysematous changes notable at 3-6 months but they are stabilized with the 
cessation of smoking. This is in contrast to emphysema seen in human habitual smokers where the 
disease usually continues to progress despite smoking cessation44,54. The cigarette smoke model is 
most useful in studies on the initiation of the disease but is costly due to the months required to 
produce a phenotype and is ill suited to study the progression of the disease. 
The first elastolytic protease-induced model of emphysema was proposed by Gross et al. in 
1965 using intratracheal administration of papain in rats55. Later studies found that instilling 
elastase (either porcine pancreatic elastase or human neutrophil elastase) into the lung was more 
effective at inducing the alveolar tissue destruction seen in emphysema. When a single dose of 
elastase is administered, it is neutralized and cleared from the lungs within 24 hours56. However, 
alveolar tissue destruction continues for weeks beyond the initial insult which is suggested to be 
due to the release of proteases by immune cells, such as macrophage elastase (MMP-12)56. 
Importantly, in contrast to the cigarette-smoke model which takes months to show a modest 
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phenotype, instillation of 3 enzymatic units (U) of elastase produces significant emphysematous 
changes by just one week. Recent work from Mitzner and colleagues demonstrated a strain-
dependent effect of the model57. Whereas C57BL/6J mice show moderate emphysematous 
changes on stereological and pulmonary function analysis with 3U of elastase, BALB/cJ mice show 
significantly more pronounced damage. For instance, at 96 days post administration of 3U of 
elastase, BALB/cJ mice exhibited a 100% increase in total lung capacity (TLC) whereas C57BL/6J 
mice showed only a 20% increase in TLC compared to control mice. Due to its ability to rapidly 
induce progressive emphysema with a single treatment, we employ the elastase-induced 
emphysema model to study the progression of the disease in BALB/cJ mice. 
 
Evaluation of lung structure and function in animal models 
In laboratory animals, emphysema is evaluated by pulmonary function tests and lung 
histology. To determine the gas exchange capacity of the emphysematous lung, the diffusion factor 
for carbon monoxide (DFCO), analogous to the diffusion capacity of the lungs for carbon monoxide 
(DLCO) used in humans, is employed. The measurement is calculated based on the net loss of CO 
after a 9 second breath hold (representing the amount of CO that diffuses into the blood) 
compared to the dilution of a tracer gas (representing the lung volume). Values for DFCO range 
from 0 (no uptake of CO) to 1 (complete uptake of CO) and in BALB/cJ mice with elastase-induced 
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emphysema, are approximately decreased by 9% compared to healthy controls (Table II). 
 
To assess the mechanical functioning of the lung in vivo, multiple measurements can be 
collected using a flexiVentTM ventilator (Scireq, Montreal, QC)58. For example, using the single 
frequency forced oscillation technique (FOT), the pressure, flow, and volume values can be fit to 
the single compartment model to calculate the resistance, elastance, and compliance of the lung. 
With the low-frequency FOT, values are fit to the Constant Phase Model59 and the input 
impedance, Newtonian resistance, tissue damping, and tissue elastance are calculated. To obtain 
quasi-static mechanical measurements, pressure-volume (P-V) loops are captured and from them 
the quasi-static compliance, total lung capacity, and residual volume are calculated. For our 
purposes, lung mechanical function changes in our mice are evaluated using the total lung 
capacity, residual volume, and quasi-static compliance. Average values of these measures for 
healthy and emphysema mice are summarized in Table II. 
 
Pathogenesis of COPD/emphysema  
Over the past six decades, many environmental factors, genes, cell types, and molecular 
mediators have been identified for their involvement in the multifaceted pathogenesis of 
COPD/emphysema. However, there remains a great paucity in the understanding of how these 










Maximal inflation at 35 cmH2O 
[mL]
1.378 mL ± 0.04391 1.791 mL ± 0.05326 ~30% ↑ Hyperinflation, "barrel chest"
Static compliance
Change in volume for any given 
applied pressure (3-8 cmH2O) 
[mL/cmH2O]





Loss of alveolar and elastic 




Trapped air volume after 
airway collapse on deflation 
[mL]
0.1615 mL ± 
0.02626
0.2924 mL ± 
0.03347
~81% ↑
Incomplete expiration due to 





Transfer of gas molecules from 
the air to the blood; 1=complete 
uptake of all CO; 0=no uptake of 
CO
0.7652 ± 0.01096 0.6965 ± 0.01190 ~9% ↓
Poor conductance of gas 
across epithelial layer due to 
tissue damage
Table II Pulmonary function measures used to assess emphysema progression in elastase model
*mean ± standard error; measurements performed at day 21 in BALB/cJ mice who received 50 μL of PBS IT on day 0
† mean ± standard error; measurements performed at day 21 in BALB/cJ mice who received  3U elastase in 50 μL sterile PBS IT on day 0
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events and factors interact to determine individual susceptibility to developing emphysema and 
what mediators propagate alveolar destruction in the progressive form of the disease. 
Emphysema is considered an immunological disorder with innate immune mechanisms 
playing a major role in the pathogenesis and progression of the disease. While some research has 
suggested a role for the adaptive immune system in the clinical severity of emphysema60, 
experiments in severe combined immunodeficiency mice have demonstrated no difference in the 
phenotype of cigarette smoke-induced emphysema compared to wild type controls61, suggesting 
the adaptive immune response is not crucial to the pathogenesis of emphysema.  
The current paradigm for the development of COPD/emphysema is that tobacco smoke 
and other noxious agents initially damage and stress alveolar epithelial cells and extracellular 
matrix leading to the degradation of tissue components and release of DAMPs 62–64. These danger 
signals then activated alveolar epithelial cells and lung macrophages to produce innate and 
inflammatory cytokines including TNFα, IL-1β, and IL-865,66. The release of IL-1β activates alveolar 
macrophages and signals them to release the neutrophil chemotactic factor, IL-8. The repeated 
damage to the lung experienced with each inhalation of smoke or particulate matter results in 
ongoing recruitment of inflammatory cells including neutrophils, monocytes, and dendritic cells to 
the lung. When these cells arrive to the damaged tissue, they release proteases and reactive 
oxygen species in order to control the perceived threat and destroy foreign materials. In an acute 
injury or infection, these damaging molecules are usually kept in balance by anti-proteases and 
anti-oxidants, however, in this state of repetitive damage, regulation is lost and the initial pro-
inflammatory response to injury results in a positive feedback loop and dysregulated repair 
process. 
The aberrant immunological processes that occur during repeated exposure to noxious 
factors results in an imbalance of protease/anti-protease activity, oxidant/anti-oxidant activity, 
and lung structure maintenance components.  
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Protease/anti-protease imbalance hypothesis 
In the early 1960s, researchers identified that a genetic deficiency in the serum protease 
A1AT led to severe early-onset emphysema40. Around the same time, Gross et al. proposed the first 
protease-induced emphysema animal model via the instillation of papain in rat lungs; together 
these findings led to the protease-anti-protease imbalance hypothesis of emphysema 
pathogenesis67.  Innate immune cells activated in response to repeated lung injury release a 
variety of proteases including neutrophil elastase, matrix metalloproteases (MMP), cathepsins, 
collagenases, and caspases that are intended to aid in the clearance of damaged tissue, wound 
healing, fibrotic development, and angiogenic remodeling68–71. Studies of human samples of 
bronchoalveolar lavage (BAL) fluid and sputum have demonstrated increased expression and 
activity of several extracellular matrix degrading MMPs including MMP-1, MMP-8, MMP-9, and 
decreased expression of the anti-proteases tissue inhibitor of metalloproteases (TIMP) 1 and 2 in 
COPD patients compared to controls72–74. Additionally, many animal models of emphysema have 
demonstrated amelioration of the phenotype with administration of anti-proteases or loss of 
MMPs51,52,75. 
Oxidant/anti-oxidant imbalance hypothesis 
The release of reactive oxygen species (ROS) from activated neutrophils, macrophages, 
and alveolar epithelial cells is an integral part of the innate immune response that is tightly 
controlled by anti-oxidants due to the damaging nature of these molecules. However, in 
dysregulated inflammatory states like emphysema, an imbalance in the amount of ROS relative to 
neutralizing species leads to tissue destruction and propagation of inflammation. For instance, 
upon phagocytosis of inhaled particulate matter in cigarette smoke, activated alveolar 
macrophages trigger the nicotinamide adenine dinucleotide phosphase (NADPH) oxidase complex 
and generate copious amounts of the superoxide anion which is then converted to hydrogen 
peroxide either spontaneously or via superoxide dismutases. The superoxide anion and hydrogen 
18 
 
peroxide then go on to interact with other molecules and form free radicals that exert a cytotoxic 
effect76. Similar to proteases, uncontrolled production or accumulation of oxidants is detrimental 
to organ structure and function, thus balance must be kept. To that end, the lungs of COPD patients 
contain significantly less superoxide dismutase than those of healthy controls77 and mice lacking 
the nuclear erythroid-related factor 2 (Nrf-2), an antioxidant transcription factor, are sensitive to 
cigarette smoke exposure; developing enlarged airways, increased inflammatory response, and 
apoptosis of epithelial and endothelial cells78.  
Lung structure maintenance imbalance hypothesis 
Following the initial damage to the lung caused by some noxious exposure, inflammation 
and tissue repair responses are initiated in an effort to restore normal lung structure and function. 
These repair processes include the release of growth factors (e.g. vascular endothelial growth 
factor [VEGF] and hepatocyte growth factor [HGF]), deposition of extracellular matrix proteins, 
and remodeling of the extracellular matrix79–82. 
One of the most important cell types in the tissue repair process is the fibroblast. In order 
to repair the parenchymal tissue damaged by cigarette smoke components and proteases released 
from inflammatory cells, fibroblasts are recruited to the injured site, differentiate into 
myofibroblasts, and synthesize protein components of the extracellular matrix as well as growth 
factors that stimulate alveolar epithelial cell proliferation79, endothelial cell survival, and 
angiogenesis80. Data from human studies have demonstrated that the lung fibroblasts from 
emphysema patients have an altered functional capacity including reduced proliferative 
capability81,83,84, increased frequency of senescence82, reduced production of hepatocyte growth 
factor and functional keratinocyte growth factor85, and decreased responsiveness to TGF-β186 
compared to healthy control patients.  
Innate immune system 
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Previous research in our laboratory has evaluated the role of neutrophils in the 
pathogenesis and progression of emphysema as neutrophils are elevated in the BAL fluid and 
sputum of COPD patients, correlate with disease severity87, and produce many of the proteases 
and oxidants implicated in the disease88. However, long term depletion of neutrophils in elastase-
treated mice had no effect on the lung histology or pulmonary function compared to neutrophil-
intact controls. While neutrophils likely still play some role in the complex mechanisms of 
initiation and progression of disease, they do not appear essential in this model thus this work will 
focus on the role of macrophages in emphysema progression. 
The implication of macrophages in the progression of emphysema stems from the finding 
that the lungs of emphysema patients have 5-10 fold more macrophages than healthy controls and 
that similar to neutrophils, this correlates with disease severity89. Further, macrophages secrete 
many effector molecules that can directly destroy extracellular matrix (e.g. MMP-9 and 12) or 
propagate inflammation (e.g. IL-8, IL-1β, IL-6, and TNF-α) 51,90,91. Unlike neutrophils, alveolar 
macrophages are long-lived self-renewing cells in abundance at baseline who orchestrate the 
alveolar cellular milieu, a role that could easily become pathogenic in a dysregulated state. 
Because tissue resident macrophages are integral to normal tissue homeostasis and 
monocytes can differentiate into macrophages, these populations have been investigated for their 
role in wound healing. In response to tissue injury, macrophages initially phagocytize apoptotic 
cells and debris, release proteases including macrophage elastase, and secrete chemokines to 
recruit other inflammatory cells to the injured tissue. Following the initial inflammation, 
macrophages undertake a tissue repair phenotype that includes the release of growth factors and 
cytokines to recruit cells such as fibroblasts and to induce local proliferation, differentiation, and 
angiogenesis92.  At this point in the repair process, macrophages acquire an anti-inflammatory 
phenotype and are responsive to immune dampening cytokines including IL-10 and secrete both 
IL-10 and TGF-β125,93. Interestingly, depending on the nature of injury (sterile or infectious) and 
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organ site, tissue resident macrophages or recruited monocytes play distinct roles in the 
pathogenesis of diseases of sterile inflammation and dysregulated wound repair such as 
athlerosclerosis92,94, myocardial infarction95, arthritis96, and emphysema68,97,98. 
Recent work from our lab found that BALB/cJ mice, a strain that is highly susceptible to 
elastase-induced emphysema, had elevated numbers of macrophages with a mixed classically 
(M1) and alternatively (M2) activated phenotype (i.e. expression of inducible nitrous oxide [inos], 
arginase 1 [arg1], found in inflammatory zone 1 [fizz1]), compared to resistant C57BL/6J mice. 
Notably, the expression of M2-associated genes in BALB/cJ mice was elevated for a prolonged 
amount of time. The M2 phenotype is associated with wound healing, tissue remodeling, and the 
resolution of inflammation and to this end includes the secretion of extracellular matrix 
remodeling proteins including MMP-2, MMP-9, and MMP-12 whose expression is strongly 
correlated with emphysema in humans and laboratory animals52,69,72,75.  
We hypothesize that in the elastase model of emphysema, the acute injury that occurs 
immediately following elastase administration creates an inflammatory environment that includes 
the release of DAMPs such as IL-3399,100, that act either directly or indirectly on lung macrophages 
to push them toward an altered repair phenotype. If lung macrophages truly are essential for the 
progression of emphysema, there is hope that targeted reprogramming of these cells could halt 
the progression of disease.  Important for the development of a protocol to reprogram lung 









The overall goal of this thesis is to determine the cellular dynamics of resident and 
recruited macrophages, monocytes, and neutrophils and the role of resident macrophages in the 
elastase-induced emphysema model in BALB/cJ mice. 
Aim 1 
Elucidate the dynamics of resident and recruited macrophages, monocytes, and 
neutrophils in the lung following administration of elastase in BALB/cJ mice. 
 
Aim 2 
Determine if the depletion of resident lung macrophages ameliorates or worsens 




MATERIALS AND METHODS 
 
Animals 
Male wild-type (WT) BALB/cJ mice were either purchased directly from The Jackson 
Laboratory at 4-6 weeks of age (Stock No. 000651, Bar Harbor, ME) or bred in-house from mice 
originally purchased from The Jackson Laboratory. Male CD11c-DTR BALB/cJ mice, originally 
purchased from The Jackson Laboratory, were bred in-house (Stock No. 004509, Bar Harbor, ME). 
All mice used in experiments were male and 6-9 weeks of age and housed under specific 
pathogen-free conditions at the Johns Hopkins Bloomberg School of Public Health and were used 
in accordance with the National Research Council’s Guide for the Care and Use of Laboratory 
Animals federal guidelines and the procedures were approved by the Johns Hopkins University 
Animal Care and Use Committee institutional review committee (Protocol number MO12H473 and 
MO15H461). Mice received filtered air (60-70% relative humidity) at 22-26⁰C, were given food 
and water ad libitum, and exposed to a 12-hour light/dark cycle. 
Intratracheal elastase administration 
Pulmonary emphysema was induced by administering 3U of porcine pancreatic elastase 
(EC-134 Elastin Products Company, Owensville, MO) via intratracheal instillation (IT). Mice were 
anaesthetized with a mixture of ketamine (100 mg/kg) and xylazine (15 mg/kg) via 
intraperitoneal injection (IP) and placed supine, suspended by their incisors using silk thread, on a 
15⁰ sloped Plexiglas platform.   The neck area was treated with 70% ethanol and a 3 mm midline 
incision was made in the skin to expose the trachea. The tongue was gently pulled forward and to 
the side while a 20-gauge catheter (Jelco Optiva®, Smith Medical, Dublin, OH) with a manually 
bent tip was inserted toward the ventral surface of the mouse. Tracheal insertion was confirmed 
by visualizing the white catheter tip through the midline incision. A 3U dose of elastase suspended 
in 50 μL of sterile 1X phosphate-buffered saline (PBS) was instilled via the inserted catheter. To 
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ensure the solution was evenly distributed throughout the lungs, the mice were immediately 
ventilated through the catheter for 15 seconds with room air at 0.1 mL tidal volume and 250 
strokes/minute using a MicroVent Ventilator (Model 848, Harvard Apparatus, Holliston, MA).  
Mice were monitored and allowed to recover for at least 2 days prior to evaluation at various time 
points post-elastase administration, as described in each experiment. 
In vivo labeling of resident alveolar macrophages 
PKH26-PCL (PKH26PCL-1KT, Sigma-Aldrich, St. Louis, MO) is a red-fluorescent dye that is 
selectively taken up by phagocytic cells due to its formation of dye aggregates. A dose of 2.5 μM 
PKH26-PCL in 50 μL of sterile 1X PBS was administered IT, as described above, 24-48 hours prior 
to elastase challenge.  
Lung macrophage depletion 
 A 100 μL dose of either clodronate (5mg/mL)-loaded liposomes (CLL) or PBS-loaded 
liposomes (PLL) suspended in sterile PBS were administered IT on days 3, 5, and 7 following 
elastase administration. To monitor depletion efficacy, a subset of mice were sacrificed 24 hours 
after each liposome treatment and at days 10 and 14 following elastase. Liposomes were 
purchased from Dr. Nico van Rooijen (Amsterdam, The Netherlands) and are formulated as 
previously described101. 
Flow cytometry 
After mice were anaesthetized with Avertin (2,2,2-tribromoethanol)the lungs were 
removed, and the large airways were dissected away from the peripheral lung tissue. Due to the 
leaky nature of blood vessels during acute inflammation following elastase administration, lungs 
were not perfused prior to removal in order to conserve the integrity of the alveolar and 
interstitial cells. Excised lungs were placed in 5 mL RPMI 1640 containing 1 mg/mL collagenase 
type II (1701-015, Thermo Fisher Scientific, Waltham, MA) and 30 μg/mL DNase I (10104159001, 
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Roche Applied Science, Indianapolis, IN), minced, and incubated at 37⁰C, 5% CO2 for 30 minutes. 
Following digestion, lung tissue was ground through a 100 μM nylon cell strainer (352360, 
Thermo Fisher Scientific, Waltham, MA) using a syringe plunger to form a single-cell suspension. 
Cells were pelleted at 1500 g at 4⁰C for 6 minutes and suspended in ACK lysis buffer (118-156-
721, Quality Biological Inc., Gaithersburg, MD) at room temperature for 5 minutes to lyse any red 
blood cells. Cells were washed in 1X PBS, strained through a 70 μM nylon cell strainer (352350, 
Thermo Fisher Scientific, Waltham, MA), and pelleted at 1500 g at 4⁰C for 6 minutes, and 
suspended in 1X PBS. Cells were counted on a hemocytometer and approximately 1 x 106 cells 
were stained in 1 mL of 1X PBS with LIVE/DEAD® Fixable Aqua Dead Cell viability dye (L34957, 
Thermo Fisher Scientific, Waltham, MA) for 30 minutes on ice in the dark. Cells were then washed 
in FACS buffer [1X PBS with 2% heated-inactivated fetal calf serum (35-011-CV, Mediatech, Inc., 
Manassas, VA)] and suspended in 100 μL FACS buffer. Because the high-affinity Fc receptor CD64 
can non-specifically bind the Fc portion of other antibodies including anti-mouse CD16/CD32 Fc 
block (553142, BD Biosciences, San Jose, CA), cells were stained separately with CD64 for 25 
minutes on ice in the dark. After washing with FACS buffer and suspending in 100 μL of FACS 
buffer, cells were incubated with anti-mouse CD16/32 Fc block for 10 minutes, and stained with 
the remaining antibody panel for 25 minutes on ice in the dark. 
 All samples were collected on a BD LSR II flow cytometer using BD FACSDiva software (BD 
Biosciences, Franklin Lakes, NJ). The LSR II configuration and voltages used to collect all samples 

























Table II BD LSR II settings
Antigen Fluorophore Clone Vendor Catalog No. Dilution
LIVE/DEAD™ Aqua ThermoFisher Scientific L34957 1:1000
CD64 PE/Cy7 X54-5/7.1 BioLegend 139314 1:50
CD45 APC/Cy7 30-F11 BioLegend 103116 1:200
Ly6C FITC HK1.4 BioLegend 128005 1:200
Ly6G Alexa Fluor 700 1A8 BioLegend 127621 1:200
I-A/I-E BV605 M5/114.15.2 BioLegend 107639 1:200
CD11b BV785 M1/70 BioLegend 101243 1:100
SiglecF BV421 E50-2440 BD Biosciences 562681 1:133
CD11c APC N418 Miltenyi Biotec 130-102-493 1:33
Table IV Flow cytometry antibody panel for detection of myeloid cell subsets in the murine lung
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Flow cytometry analysis 
All data was analyzed using FlowJo software (TreeStar, Inc., Ashland, OR). Because the 
total number of cells changes over the course of inflammation and emphysema progression, 
quantifying cell dynamics by directly using the flow cytometry data output of percentage of a 
certain population can introduce bias therefore, cells per lung were quantified in the following 
manner. The percentage of live, singlet cells was calculated by first gating on “cells” using forward 
scatter area (FSC-A) and side scatter area (SSC-A) to exclude red blood cells and debris (Figure 5). 
Forward scatter height (FSC-H) and FSC-A were used to gate on singlets and from this population, 
live cells were identified using LIVE/DEAD® and side scatter height (SSC-H). The frequency of 
live, singlet, cells was applied to whole lung hemocytometer calculations to compute an 
approximate number of cells per lung. Notably, lungs were harvested without perfusing in order 
to maintain certain immune cell populations that could be lost during perfusion. However, this 
means that calculations reflect not only cells of lung tissue but also of the vascular space, obviously 
influenced by the amount of hemorrhaging. To account for spectral overlap and issues of 
compensation, fluorescence-minus-one (FMO) controls were used to define all gates. Once gates 
were defined, the gated population’s percentage of live, singlet, cells was applied to the calculated 




FIGURE 5 Flow cytometry gating scheme  
Diffusion factor for carbon monoxide (DFCO) measurement 
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 Mice were anaesthetized with a mixture of ketamine (100 mg/kg) and xylazine (15 mg/kg) 
IP and tracheostomy was performed using an 18 G stub needle cannula. The lungs were then 
inflated with 0.8 mL of gas containing approximately 0.5% carbon monoxide (CO), 0.5% neon 
(insoluble inert tracer gas), and room air. After holding the lungs inflated for 9 seconds, 0.8 mL of 
gas was quickly withdrawn from the lung and diluted with 2 mL of room air to ensure all sample 
gas cleared the system. The exhaled gas was then injected into a Micro GC gas chromatograph 
(INFICON, Micro GC Model 3000A, East Syracuse, NY) to measure the concentration of Ne and CO. 
The process was repeated a total of three times per animal and the average Ne and CO 








Equation for calculation of DFCO where “9” subscript refers to the gases after the 9 second breath hold and “C” subscript 
refers to the calibration gases. 
 
Pulmonary mechanics and quasi-static pressure-volume relationships 
 Following DFCO measurements, mice were given an intramuscular injection of 
succinylcholine (75 mg/kg) to induce paralysis. They were then connected to a flexiVentTM 
ventilator (Scireq, Montreal, QC), providing a constant-volume ventilation of 100% oxygen at tidal 
volume 10 mL/kg and rate of 150 breaths per minute, with a positive end-expiratory pressure 
(PEEP) of 3 cmH2O. After 3 minutes of ventilation, the lungs were inflated to 30 cmH2O for 5 
seconds and returned to normal ventilation for 1 minute. Respiratory mechanics were measured 
under closed chest conditions by applying an oscillatory pressure (FOT) to the lungs and 
measuring flow responses to the applied pressures. Before taking the FOT measurement, 
conventional single-compartment mechanics were measured with 2 seconds of a 2.5 Hz sinusoidal 
oscillation to obtain respiratory system resistance (Rrs), dynamic compliance (Crs), and elastance 
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(ErS)103. Newtonian airway resistance (Rn), tissue damping (G), and tissue elastance (H) were 
obtained by performing the broadband FOT maneuver and analyzing the constant phase model. 
 Next, the lung was sealed off for 4 minutes by closing the stopcock leading to the cannula, 
allowing for the absorption of all gas, and resulting in a lung volume of zero. Quasi-static P-V 
curves were generated via a previously detailed system104. In brief, the system is comprised of 5 
mL glass syringe filled with an initial volume of 3 mL of air, which is mounted on a dual infusion-
withdrawal syringe pump (model 55-2226, Harvard Apparatus, Holliston, MA). A linear 
displacement transformer (model 244-000, Transtek, Ellington, CT) measures the air volume 
delivered to the lung and a differential-pressure transducer (PX-137, Omega Engineering, 
Stamford, CT) measures the airway pressure. The P-V curve generated from measured airway 
pressure and volume was recorded on a PowerLab digital data acquisition system 
(ADInstruments, Colorado Springs, CO). During the initial inflation of the degassed lung, a flow 
rate of 1 mL/min was employed to avoid excessive pressure. The flow rate was increased to 3 
mL/min until a pressure of 35 cmH2O, at which point the pump was immediately reversed to 
deflate the lung until obtaining a pressure of -10 cmH2O. Two additional P-V loops from 0-35 
cmH2O were obtained to ensure there was no obstruction or leak in the system or lung. For each 
mouse, total lung capacity (TLC) and residual volume (RV) were defined as the volume at 35 
cmH2O and -10 cmH2O, respectively. Quasi-static compliance of the respiratory system (C-stat) 
was defined as the slope of the most linear portion of the P-V curve (between 3 and 8 cmH2O). 
 
Statistical Analysis 
 Differences between groups were analyzed by either a two-tailed unpaired t-test 
(Student’s for equal variances or Welch’s for unequal variances). The threshold of significance was 






Part 1: What are the dynamics of resident and recruited macrophages, monocytes, 
and neutrophils in the lung following administration of elastase in BALB/cJ mice? 
 
Flow cytometry 
 A 10-color flow cytometry panel was designed to distinguish alveolar macrophages, 
interstitial macrophages, monocytes, and neutrophils, as summarized in Table IV. To differentiate 
resident and recruited lung cells, the dye PKH26-PCL was given prior to administering elastase 
and was detected by flow cytometry using the PE channel. Staining alveolar macrophages with 
PKH26-PCL has been previously shown by our lab and others to stably label phagocytic lung cells 
for up to 30 days in the naïve lung.  Alveolar macrophages have an extremely low proliferation 
rate (half-life of ~12 months) in the absences of lung injury25. However, given the ensuing 
inflammation following elastase challenge, PKH26-PCL was given in the 24-48 hour time point 
prior to elastase for all mice to account for any influence in the time from labeling with PKH26-
PCL and elastase challenge. 
 The gating schematic used to identify macrophage, monocyte, and neutrophil populations 
is displayed in Figure 5 and the markers used to classify each cell type are summarized in Table 
V.   
 
 Under steady state conditions, alveolar macrophages do not express CD11b however, 
previous research in our laboratory has demonstrated that alveolar macrophages upregulate 
Cell type Antigens
Alveolar macrophage CD45
+, CD64+, CD11c+, SiglecF+
CD11b+ alveolar macrophage CD45
+, CD64+, CD11c+, SiglecF+, CD11b+
Interstitial macrophage CD45
+, CD64+, CD11c+, SiglecF-, CD11b+, MHC II+
Ly6C+ monocyte CD45
+, CD11b+, Ly6G-, Ly6C+
Neutrophil CD45
+, CD11b+, Ly6G+
Table V Surface antigens used in flow cytometric immunophenotyping
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CD11b during inflammation. To this end, we decided to define alveolar macrophages by the 
antigens CD64, CD11c, and SiglecF and stratify this population by CD11b expression. 
Based on previous data regarding the general inflammatory environment over the course 
of elastase-induced lung injury and subsequent emphysema, we chose to study the immune 
environment at 2, 4, 7, 10, and 14 days post-elastase administration. Briefly, mice were given 
PKH26-PCL IT between 24 and 48 hours prior to receiving 3U of elastase IT and then sacrificed for 
analysis by flow cytometry at the designated time points (Figure 6). Naïve mice were sacrificed 
24-48 hours following administration of PKH26-PCL.  
 
FIGURE 6 Experimental design for elucidating dynamics of resident and recruited myeloid 
cells in the elastase treated lung Mice were give 2.5 μM of PKH26-PCL dye IT 24-48 hours prior 
to the administration of 3U of elastase IT. D0 indicates mice that received PKH26-PCL dye and 
were sacrificed 24-48 hours after administration. All mice were sacrificed at the indicated time 
points and flow cytometric analysis was performed the same day. 
 
Whole lung cell count  
At baseline, male BALB/cJ mice have an average of 1 x 107 cells in the unperfused lung 
(Figure 7). At two days following elastase challenge, there is significant hemorrhaging, cellular 
infiltration, and presumably proliferation throughout the lung resulting in the number of cells 
doubling.  The cellular expansion peaked at day 4 and by day 7 much of the hemorrhaging had 
subsided and lung cell numbers decline to around 1.4 x 107 cells per lung at day 14 post-elastase. 
The response between days 0 and 4 is reflective of the acute injury phase of elastase-induced 





FIGURE 7 Whole lung cell count following elastase administration Whole lung cell counts 
were derived by applying flow cytometry gating calculations of the percentage of collected cells 
that were live and singlet, to hemocytometer counts of cells. Each point represents the mean ± 




In preliminary studies, the optimal concentration of PKH26-PCL, 2.5 μM, was determined 
by titrating the dose of dye and analyzing by flow cytometry to achieve a clear positive shift on 
flow cytometry.  The overwhelming majority of PKH26-PCL+ cells were alveolar or interstitial 
macrophages, non-phagocytic cells such as epithelial calls and fibroblasts were PKH26-PCL (data 
not shown). We aimed for a conservative concentration of dye to avoid the possibility of excess 
dye exiting the lung and staining peripheral phagocytes or staining infiltrating phagocytes 
following elastase administration.   
While PKH26-PCL+ cells included both alveolar and interstitial macrophages, a majority of 
the labeled cells had a surface phenotype of alveolar macrophages. The reason for the lower 
number of labeled interstitial macrophages is unclear but the less efficient labeling may have been 
due to their spatial location and reduced access to the dye. The percentages of alveolar 
macrophages, interstitial macrophages, neutrophils, and monocytes that were PKH26-PCL+ are 
displayed in Figure 8. Importantly, the percentage of monocytes that were PKH26-PCL+ was 
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exceedingly low at all time points. In the naïve lung, less than 2% of the PKH26-PCL+ were 
neutrophisl, however, this increased to almost 8% on day 7 post-elastase and subsequently 
declined to less than 4% by day 10. Upon analyzing these PKH26-PCL populations by SSC-A and 
FSC-A, it appears they are macrophages that are either ending up in the neutrophil gate due to the 
gating strategy applied or they are macrophages that efferocytosed neutrophils and gained Ly6G 
expression via trogocytosis105. Overall, the utilization of PKH26-PCL dye appears to be a reliable 





FIGURE 8 Efficacy of PKH26-PCL labeling of resident lung cells Data are presented as the 
percentage of a given cell type (e.g. alveolar macrophages) that are PKH26-PCL+ as analyzed by 
flow cytometry. Alveolar macrophages are defined as CD64+, CD11c+, SiglecF+ and on average 94% 
are PKH26-PCL+ at D0 and D2, 85% are PKH26-PCL+ at D4 and D7, and 76% and 56% are PKH26-
PCL+ on D10 and D14, respectively. Interstitial macrophages are defined as CD64+, CD11c+, SiglecF-, 
CD11b+, MHCII+ and on average 40% are PKH26-PCL+ on D0, 22% are PKH26-PCL+ on D2, 33% are 
PKH26-PCL+ on D4 and D14, and 45% are PKH26-PCL+ on D7 and D10. Of Ly6C+ monocytes ≤2% 
are PKH26-PCL+ at all time points. Of Neutrophils ≤2% are PKH26-PCL+ at D0 and D2, 5.5% are 
PKH26-PCL+ at D4, 7.8% are PKH26-PCL+ at D7, and 3.5% are PKH26-PCL+ at D10 and D14. Each 





The alveolar macrophage population fluctuates over the course of the inflammatory 
response to elastase-induced damage with a return to a near-baseline level around day 14, which 
is consistent with other lung injury models25,106. From the time of elastase administration until day 
4 post-elastase, there is a 2.6-fold contraction of the alveolar macrophage population (Figure 9A, 
black line). Between days 4 and 10 post-elastase, that population doubles and is followed by a 
subsequent decline out to day 14.  
After the administration of elastase, a subpopulation of resident alveolar macrophages 
upregulates CD11b surface expression. This population almost doubles by day 2 post-elastase 
(Figure 9A, blue line). By day 7, the population reaches over 5 times that of the naïve lung. 
Between days 7 and 10, the CD11b+ resident alveolar macrophage population either contracts 
through apoptosis, migration to the draining lymph nodes, or downregulation of CD11b, reaching 
a population close to baseline by day 14. 
Stratifying alveolar macrophages by PKH26-PCL staining to identify resident cells (Figure 
9B) demonstrates that the overall alveolar macrophage population dynamics are primarily 
attributable to resident cells while a small population of PKH26-PCL- alveolar macrophages 
emerges around day 4 when it more than doubles and continues to increase through day 14 post-
elastase.  
Overall, the expansion of alveolar macrophages in the lung between days 7 and 10 post-
elastase appears to be primarily attributable to local cell proliferation as there is an increase in the 
number of PKH26-PCL+ cells. Additionally, there is a subpopulation of alveolar macrophages that 







FIGURE 9 Alveolar macrophage dynamics in the lung following elastase administration 
Alveolar macrophages are defined as CD64+, CD11c+, SiglecF+ and are stratified by (A) CD11b 
expression and (B) PKH26-PCL, where PKH26-PCL+ cells represent resident alveolar 
macrophages. Each point represents the mean ± SEM with an average of 9 mice per time point. 
 
Interstitial macrophages 
 The resident interstitial macrophage population undergoes proliferation following the 
administration of elastase with an almost 32 fold increase from baseline by day 4 (Figure 10). The 
population then contracts to a population size approximately 6-fold higher than baseline by day 
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14. The PKH26-PCL- population of interstitial macrophages shows a similar dynamic, increasing 
over 32 fold to peak by day 4 post-elastase. By day 14 post-elastase, the PKH26-PCL- population 
decreases with kinetics similar to that observed for the PKH26-PCL+ cells.  
To facilitate the comparison of the dynamics of each macrophage population, data for the 
three subsets have been plotted together in Figure 11. Interestingly, in Figure 8 there is a gradual 
but significant decline in the percentage of positive alveolar macrophages from day 7 to day 14 
post-elastase. This could be due either to dilution of the dye through multiple cell divisions, 
proliferation of unlabeled resident alveolar macrophages, or through the differentiation of PKH26-
PCL- interstitial macrophages into alveolar macrophages. Figure 11B shows a steady increase in 
the number of PKH26-PCL- alveolar macrophages from day 4 to day 14 while at the same time 
there is a steady decline in interstitial macrophages following their sharp peak at day 4. Further, 
the increase in the absolute number of PKH26-PCL- alveolar macrophages mirrors the decrease in 
the number of PKH26-PCL- interstitial macrophages. In support of this hypothesis is a 2007 
publication by Landsman and Jung demonstrating that following alveolar macrophage depletion, 
interstitial macrophages proliferated and migrated into the alveolar space and were replenished 
by Ly6C- monocytes. Our observed Ly6C+ monocytes dynamics do not appear to contribute to the 
PKH26-PCL- interstitial macrophage expansion so perhaps it is due to Ly6C- monocytes as the 
authors witnessed, or simply local proliferation of unlabeled resident interstitial macrophages. 















FIGURE 10 Interstitial macrophage dynamics in the lung following elastase administration 
Interstitial lung macrophages are defined as CD64+, CD11c+, SiglecF+, CD11b+, MHCII+ and are 
stratified by PKH26-PCL labeling. Each point represents the mean ± SEM with an average of 9 mice 





FIGURE 11 Macrophage subset dynamics in the lung following elastase administration (A) 
PKH26-PCL+ cells (B) PKH26-PCL- cells. (C) All macrophages independent of PKH26-PCL staining; 
alveolar macrophages are stratified by CD11b expression so that the total of the black and blue 
bars represents the total number of alveolar macrophages. Each point/bar represents the mean ± 
SEM with an average of 9 mice per time point. 
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The number of Ly6C+ monocytes in the lung more than doubles by day 2 post-elastase, 
which is expected due to the significant hemorrhaging and acute injury to the lung (Figure 12). By 
day 4, the number of monocytes peaks at a little under one million cells and by day 14, it returns to 
baseline. Interestingly, the magnitude of infiltrating monocytes is less than one might expect given 
the significant damage to the lung. This may be a result of the markers we employed to identify 
Ly6C+ monocytes as infiltrating cells may be altering their phenotype immediately upon entry into 
the lung and thus would not be captured in our panel. 
 
FIGURE 12 Ly6C+ monocyte dynamics in the lung following elastase administration Each 






Given the significant damage to the lung that occurs immediately following elastase 
administration, the rapid influx of neutrophils into the lung is expected. By day 2 post-elastase, the 
number of neutrophils triples and by day 4 begins to gradually decline to baseline, by day 14 
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(Figure 13). The relative dynamics of the macrophage subsets, monocytes, and neutrophils are 









FIGURE 13 Neutrophil dynamics in the lung following elastase administration Each point 




FIGURE 14 Myeloid cell dynamics in the lung following elastase administration Each point 





Part2: Does depletion of lung macrophages impact the cellular response 
and functional parameters after elastase challenge? 
 
Resident macrophage depletion 
 Because alveolar macrophages are long-lived cells that produce many of the effector 
molecules implicated in the progression of emphysema, we hypothesized that they may play a role 
in the progressive alveolar destruction and declining lung function following elastase 
administration.  
 Previous research in the lab attempted to delineate the importance of alveolar 
macrophages during the initiation and progression of elastase-induced emphysema by depleting 
alveolar macrophages via intratracheal aspiration of CLL or PLL 1 day prior to elastase challenge 
and at days 2, 7, or 14 post-elastase. Examination of histopathological sections indicated there was 
no difference between mice given PLL or CLL at any of the studied time points. However, while 
depletion efficacy was 83% when administered 1 day prior to elastase challenge, the efficacy 
declined to 45%, 68%, and 42% at days 2, 7, and 14 post-elastase, respectively. 
 We hypothesized that the poor depletion efficacy at time points following elastase 
administration was either secondary to a physical barrier to liposomes reaching the macrophages 
due to the amount of hemorrhaging and edema in the lung, or due to the animals not being able to 
aspirate well enough once acute lung injury and emphysema were induced. In an attempt to 
improve the depletion efficacy, we tested the effect of giving a second dose by administering 
liposomes on days 3 and 4 via intratracheal aspiration. However, the mice barely survived the first 
dose on day 3 and two thirds of the mice died immediately following the second dose on day 4. 
Because death was instant, we presumed it was due to an overwhelming amount of fluid in lungs 
already inundated with edema and blood, essentially drowning the mice. Due to this delicate time 
point, we repeated the pilot experiment, instead giving liposomes on days 4 and 5 post-elastase. 
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While all of the mice survived the treatments, the depletion efficacy 24 hours after the second 
dose was only 67%.  
 Due to the unsatisfactory depletion efficacy of intratracheally aspirated CLL, we decided to 
attempt to deplete alveolar macrophages using BALB/c CD11c-diphtheria toxin receptor (DTR) 
mouse model. Because mice do not normally express the diphtheria toxin receptor, transgenic 
mice that express the diphtheria toxin receptor in a given cell type will deplete this cell when 
administered diphtheria toxin. CD11c-DTX mice express the simian diphtheria toxin receptor 
under control of the murine integrin alpha X (Itgax – CD11c) promotor, typically expressed 
primarily on dendritic cells. Because alveolar macrophages express high levels of CD11c, we were 
able to administer diphtheria toxin directly to the lung and primarily deplete alveolar 
macrophages. The benefit of using diphtheria toxin over liposomes is that diphtheria toxin does 
not have the level of viscosity that liposomes have and can be given in a 50 μL volume as opposed 
to 100 μL. A series of pilot experiments were performed to evaluate the most efficient dose of 
diphtheria toxin in terms of depletion efficacy and animal survival as repeated doses of diphtheria 
toxin have proven to be lethal. We found a dose of 90 ng in 50 μL of sterile 1X PBS to best achieve 
this (data not shown) and gave the toxin solution via intratracheal aspiration 1 day prior to 
elastase challenge and on days 2, 4, and 6 post-elastase in order to ensure continued depletion of 
the population. Unfortunately, while we found the depletion efficacy to be between 80-89% on 
days -1, 2, and 6 and 45-77% efficacy on day 4, mice experienced significant weight loss and were 
quite ill by day 7. 
 Due to the mediocre depletion efficacy and illness experienced by the CD11c-DTR mice, we 
decided to attempt to employ CLL again. During intratracheal aspiration following elastase 
administration, mice noticeably have difficulty aspirating liquid and appear unable to make the 
effort for deep inspiration, necessary for effective liposome administration into the alveolar space. 
To address this issue, we explored giving the liposomes IT where the mice are intubated with a 
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cannula, the liposome solution is instilled via pipette, and the cannula is connected to a room-air 
ventilator to ensure the solution is distributed evenly throughout the lung and to give the animals 
supplemental air during this process. We determined that mice were able to tolerate three doses 
of liposomes given IT on days 3, 5, and 7 post-elastase with a depletion efficacy of 97% following 
the third dose. The timing of depletion was chosen based on the alveolar macrophage dynamics 





 Table VI summarizes the depletion efficacy of alveolar macrophages at 24 hours following 
each liposome dose and at 3 and 7 days following the third dose of liposomes (days 10 and 14 
post-elastase). Mice evaluated on day 4 received 1 dose of liposomes on day 3 post-elastase, mice 
evaluated on day 5 received a total of 2 doses of liposomes on days 3 and 5 post-elastase, and mice 











4 3 85.00 92.69
6 3, 5 94.61 91.69
8 3, 5, 7 98.06 91.70
10 3, 5, 7 91.41 94.06
14 3, 5, 7 92.63 92.82
Table VI Alveolar macrophage depletion efficacy*
* CD64+, CD11c+, SiglecF+ alveolar macrophages of elastase+CLL mice vs elastase only mice
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Depletion of resident alveolar macrophages was maintained between approximately 92-94% from 
day 4 through at least day 14 post-elastase. Regarding the entire alveolar macrophage population 
(i.e. not taking into account PKH26-PCL labeling), the depletion efficacy was maintained between 







FIGURE 15 Experimental design to evaluate clodronate-loaded liposome depletion efficacy 
and cellular dynamics Mice were given 2.5μM of PKH26-PCL dye IT 24-48 hours prior to 
administration of 3U of elastase IT. Mice were then administered 100μL of either PLL or CLL IT as 
a total of one dose at D3; two doses at D3, D5; or three doses at D3, D5, D7. Mice were sacrificed 
and flow cytometric analysis was performed 24 hours following the last liposome treatment and at 
days 3 and 7 following the final D7 dose. 
 
Cell dynamics following macrophage depletion 
Alveolar macrophages 
The resident alveolar macrophage (CD64+, CD11c+, SiglecF+, CD11b+, PKH26-PCL+) 
population in mice that received elastase and CLL (E+CLL) was on the order of 11.9 x 103 cells 
following one dose of liposomes and was 1.84 x 103 cells following the third dose which remained 
stable at 1.8 x 103 cells one week later (Figure 16A). This is in contrast to mice receiving elastase 
and PLL (E+PLL) whose resident alveolar macrophage population steadily increased from 1.5 x 
103 cells following a single dose of PLL until reaching 221.7 x 103 cells one week following the last 
dose of liposomes.  
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Interestingly, E+PLL mice has almost an order of magnitude fewer alveolar macrophages 
compared to mice given elastase-only (Figure 16B). This population undergoes a steady 
expansion until day 10 when there is a doubling of cells at day 14. Conversely, in the elastase-only 
mice, the resident alveolar macrophage population doubles between days 4 and 7 and 
subsequently declines to about half the population of cells in the naïve lung, by day 14. 
Similar to the results from Aim 1, a subpopulation of alveolar macrophages in the 
elastase+liposome model upregulate CD11b expression. However, in E+CLL mice, the population 
of resident CD11b+ alveolar macrophages is quite small and fairly constant between days 4 and 14 
post-elastase (data not shown). In mice receiving E+PLL, the CD11b expression dynamics are 












macrophage dynamics in the lung following elastase administration (A) Dynamics of resident 
alveolar macrophage (CD64+, CD11c+, SiglecF+, CD11b+, PKH26-PCL+) following administration of 
E+PLL or E+CLL, n=3/group (B) Dynamics of resident alveolar macrophages in mice who received 









Interstitial macrophages are generally considered to be unaffected by IT and IV 
administration of CLL – possibly due to their microanatomical location or an inherent decreased 
phagocytic capacity107,108. Indeed, in comparing the number of interstitial macrophages in mice 
who received E+CLL with those who either received E+PLL or elastase-only, the E+CLL mice 
actually had a proliferation of cells rather than a depletion.  
Figure 17A shows the overall dynamics of interstitial macrophages in E+PLL vs E+CLL 
mice. The interstitial macrophages double between the first and second dose of CLL while there is 
a gradual decline in the number of resident interstitial macrophages from the first dose of PLL to 7 
days after the third dose. Between 24 and 72 hours after the third dose of CLL there is another, 
albeit smaller, proliferation of the resident population, which then declines to a similar sized 


































FIGURE 17 Interstitial macrophage dynamics in the lung following elastase and liposome 
treatment (A) Interstitial macrophage dynamics of mice who received elastase (D0) and PLL or 
CLL, n=3/group (B) Interstitial macrophage dynamics of mice who received elastase and 








The Ly6C+ monocyte population decreases between the first and second doses of CLL by 
about half (Figure 18A). This population subsequently peaks between 24 and 72 hours following 
the third dose of liposomes until declining to baseline 5 days later. The decline in Ly6C+ monocytes 
between the first and second CLL doses could be due to phagocytosis of liposomes by the first 
round of infiltrating cells or of Ly6C+ monocytes changing their phenotype and differentiating into 
interstitial macrophages. 
In the PLL treated mice, there is a steady increase in the number of Ly6C+ monocytes 
throughout the measured time course that culminates in a population of monocytes that is triple 




FIGURE 18 Ly6C+ monocyte dynamics in the lung following elastase and liposome treatment 
(A) Ly6C+ monocyte dynamics in mice who received E+PLL or E+CLL, n=3/group (B) Ly6C+ 







The neutrophil population following the first dose of CLL is about 3-fold higher than the 
population following PBS-loaded liposome treatment, likely due to neutrophils being recruited to 
clean up apoptosed macrophages (Figure 19A). This is supported by the emergence of a PKH26-
PCL+ population of neutrophils following clodronate-loaded liposome administration which 
occurred at least 8 days following PKH26-PCL administration. 
Between the first and second dose of CLL, the neutrophil population in the lung decreases 
by about 1.6 million cells but rebounds 3-fold that after the third dose of CLL. By day 7 following 
the third dose of CLL, the neutrophil population is similar to that of mice who received PLL and 






Neutrophil dynamics in the lung following elastase and liposome treatment (A) Neutrophil 
dynamics in mice who received E+PLL or E+CLL, n=3/group (B) Neutrophil dynamics in mice who 





Pulmonary function following macrophage depletion 
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The experimental design for the evaluation of emphysema severity following lung 








FIGURE 20 Experimental design for the analysis of the effect of macrophage depletion on 
emphysema severity Mice were given either 50 μL of sterile 1X PBS or 3U of elastase in 50 μL of 
sterile 1X PBS on D0 and received a total of 3 doses of 100μL of CLL or PLL on days 3, 5, and 7 
post-elastase. Mice were sacrificed and underwent pulmonary function testing on day 21 post-
elastase.  
Abbreviations: DFCO, diffusion factor for carbon monoxide; TLC, total lung capacity; RV, residual volume; C-
stat, quasi-static compliance. 
 
Diffusion factor for carbon monoxide  
The DFCO is a measure of the functional capacity of the alveolar-capillary interface and is 
analogous to the DLCO used in humans. Values range from 0-1, with 0 being no uptake of carbon 
monoxide into the blood, and 1 being complete uptake. Low DFCO or DLCO values can be associated 
with various pathologies including decreased alveolar surface area and capillary blood volume as 
seen in emphysema109, cellular infiltration and edema as seen in pulmonary infection, and 
interstitial thickening as seen in pulmonary fibrosis.   
Figure 21A summarizes DFCO measurements from mice who received elastase or PBS 
control and either CLL or PLL liposomes as well as the standard data for healthy (PBS-only) and 
emphysematous (elastase-only) BALB/cJ mice, as previously determined in the lab. The DFCO 
values for mice who received E+CLL were significantly lower than mice who received E+PLL 
(mean ± standard error (SE), 0.5522 ± 0.01325 vs 0.6286 ± 0.01577, p=0.0049) as well as mice 
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who received elastase-only (0.6965 ± 0.01190, p<0.0001). Notably, there was no significant 
difference in the DFCO of mice who received E+PLL and mice who received elastase-only, which 
would suggest that the noted differences are independent of any liposome-mediated processes 
and are instead through some mechanism related to the depletion of alveolar macrophages. 
Conversely, in comparing the DFCO of PBS+PLL mice and PBS-only mice, there is a statistically 
significant difference, however, this may not be physiologically significant (difference between 
means: -0.03390 ± 0.01363). 
Total lung capacity 
Total lung capacity is a measure of the maximal inflation volume of the lung.   TLC in mice 
is calculated at a pressure of 35 cmH2O. Lung hyperinflation, a hallmark of emphysema, is 
pathologically associated with increased compliance of the lung and clinically results in increased 
air trapping and labored breathing110. 
In mice who received E+PLL or E+CLL, the TLC was significantly greater than that of mice 
who received elastase-only (Figure 21B). The TLC of mice who received E+PLL was 23% greater 
than elastase-only mice (p=0.0012) and it was 33% greater in mice who received E+CLL compared 
to elastase-only mice (p<0.0001).  
In mice who received PBS+CLL, the TLC was 11% greater than mice who received PBS-only 
(p=0.0089) and was 9% greater than mice who received PBS+PLL (p=0.0172). There was no 




The residual volume (RV) is the amount of air that is trapped in the lung following forced 
expiration or in the case of laboratory animals, following deflation of the lung. Residual volume is 
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increased in emphysema where there is decreased elastic recoil, a characteristic of the lung 
necessary to force inspired air out33.  
The RV in mice treated with E+CLL is 28% greater than in mice treated with elastase-only 
(p=0.0240) and is 32% greater than in mice treated with E+PLL (p=0.0185) (Figure 21C). There is 
no significant difference in RV between mice treated with E+PLL and mice treated with elastase-
only. Further, the administration of PLL or CLL showed no effect on RV in PBS treated mice. 
Quasi-static compliance 
Compliance is a pulmonary function metric that indicates how easily the lung expands at a 
given pressure and is influenced by the elasticity of lung tissue as well as the surface tension in the 
alveoli. In patients with emphysema, the compliance of the lung is significantly increased due to 
the decreased elastic recoil of the lung and increased surface tension in the alveoli related to their 
decreased surface area.  
Mice who received E+ PLL or E+CLL, had a significant increase in lung compliance 
compared to mice treated with elastase-only (17%, P=0.0057 and 18%, p=0.0070, respectively) 
(Figure 21D). Conversely, mice treated with PBS+CLL and not PBS+PLL, had a significant increase 
in lung compliance compared to mice treated with PBS-only or PBS+PLL (10%, p=0.0495 and 




FIGURE 21 Pulmonary function tests following elastase and liposome treatment Data for 
PBS-only and elastase-only groups are from previous pooled experiments in our lab where PBS-
only indicates male BALB/cJ mice given 50 μL 1X PBS IT on D0 and elastase-only indicates male 
BALB/cJ mice given 3 U elastase suspended in 50 μL 1X PBS IT on D0 with all pulmonary function 
measures performed on day 21 post-elastase. PBS+PLL/CLL = 1X PBS IT on D0, PLLCLL on D3, D5, 
D7; Elastase+PLL/CLL= 3 U elastase IT on D0, PLLCLL on D3, D5, D7; with all pulmonary function 
measures performed on day 21 post-elastase. n=5 for all groups except n=6 for E+PLL. t-test 








To gain a more complete understanding of the cellular environment following elastase 
challenge in BALB/cJ mice, flow cytometry was employed. While previous research in the lab had 
characterized cells in the BAL, this methodology is susceptible to inefficient and variable recovery 
of cells, the possibility that elastase challenge enhances recovery of cells, and limited ability to 
sample cells from the interstitial or vascular compartments. The lab has also performed 
preliminary characterization of myeloid cells using flow cytometry on whole lung homogenates, 
however, this was performed using a BD FACSCalibur which is limited to four fluorescent 
parameters and given the sensitivity of the FITC channel to auto-fluorescence, our research was 
primarily limited to three fluorescent parameters. This methodology, while useful for preliminary 
analysis, did not allow us to capture a detailed snapshot of cellular dynamics. Further, due to the 
limitation of the number of fluorochromes that could be used on the FACSCalibur, we were unable 
to gate out dead cells which can impact flow cytometry interpretation as antibodies can non-
specifically bind to dead cells.  
A 10-color flow cytometry panel was developed based on current literature and previous 
work in the lab19,111,112. Antibodies were optimized to minimize the influence of auto-fluorescence 
and provide the best discrimination between cellular populations. To distinguish CD11b+ dendritic 
cells (DCs) from interstitial macrophages, we used the high-affinity Fc-γ receptor I (FcγRI), CD64, 
which is only expressed on macrophages, monocytes, and some neutrophils113. Of note, we did not 
focus on dendritic cell populations in this analysis but with the inclusion of additional markers 
such as CD103 and CD24 this could be accomplished. 
Our decision to identify only Ly6C+ monocytes was the product of poor availability of 
antibodies that could clearly discriminate infiltrating monocyte subpopulations. Characteristically, 
there are thought to be two main monocyte populations: “classical” monocytes, which emigrate 
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from the bone marrow and infiltrate sites of inflammation, and “patrolling” monocytes, which 
circulate throughout the body during steady-state conditions and replenish certain macrophage 
and dendritic cell populations. Classical monocytes are typically characterized by their high 
expression of Ly6C and the chemokine receptor CCR2, as well as adhesion molecules including, 
but not limited to, L-lectin (CD62L), P-selectin glycoprotein ligand 1 (PSGL1), lymphocyte 
function-associated antigen 1 (LFA1), and macrophage receptor 1 (MAC1)95,114,115. While in 
circulation, Ly6C+ monocytes transition into Ly6C- monocytes. Patrolling monocytes are defined 
by a low expression of Ly6C and a high expression of the chemokine receptor CX3CR1.  
If a suitable antibody panel can be derived, future investigation into the contribution of 
Ly6C- monocytes to the lung macrophage populations and their role in disease severity and 
progression should occur as they appear to play significant and disparate roles in other sterile 
inflammation models. For instance, using a liver fibrosis murine model, Ramachandran and 
colleagues demonstrated that Ly6C- monocytes were the main source of MMPs during liver wound 
healing and scar remodeling whereas Ly6C+ monocytes were primarily responsible for the 
formation of fibrotic tissue116. Conversely, during healing following myocardial infarction, Ly6C+ 
monocytes have been associated with proteolytic, inflammatory functions and Ly6C- monocytes 
have been associated with the orchestration of accumulation of myofibroblasts, collagen 
deposition, and angiogenesis117. Continuing to develop antibodies with improve specificity and 
sensitivity will undoubtedly aid in our understanding of the complex immune environment in the 
lung following elastase challenge. 
Aim 1: Elucidate the dynamics of resident and recruited macrophages, monocytes, and 
neutrophils in the lung following administration of elastase in BALB/cJ mice. 
In order to test the effect of macrophage depletion on the severity and progression of 
elastase-induced emphysema, it was necessary to first evaluate the cellular dynamics following 
administration of elastase in BALB/cJ mice. We found that the alveolar macrophage population 
61 
 
(CD64+, CD11c+, SiglecF+) underwent an initial contraction with 2.6-fold fewer cells at day 4 post-
elastase compared to the naïve lung which then rebounded to about 3/4 that of the naïve lung at 
day 10 and subsequently declined to about half the population of the naïve lung by day 14. We 
hypothesize that this contraction is due either to macrophage cell death (apoptosis, autophagy, or 
oncosis) secondary to efferocytosis of infiltrating neutrophils or macrophage migration to the 
draining lymph node following neutrophil efferocytosis.  Under normal inflammatory conditions, 
macrophages engulf apoptopic leukocytes to avoid their secondary necrosis and aid in the 
resolution of inflammation. During this process, they accumulate reactive oxygen species which 
are normally controlled and migrate to the draining lymph nodes. However, in many chronic 
inflammatory conditions such as artherosclerosis, macrophages undergo excessive oxidative burst 
secondary to the phagocytosis of apoptotic cells and become apoptotic themselves118,119. In order 
to further delineate the alveolar macrophage dynamics in our model, studies evaluating the 
draining lymph nodes by flow cytometry and in vitro microscopy assays to evaluate cell death 
should be performed.  
To evaluate if the increase in the number of alveolar macrophages at day 7 was due to local 
proliferation of the resident population or differentiation of recruited peripheral blood 
monocytes, we employed PKH26-PCL staining to selectively label the phagocytic cells in the lung 
prior to elastase administration (defined broadly as resident lung macrophages). Our results 
indicate that vast majority of expansion on day 7 can be attributed to local proliferation of the 
resident population. The proliferation that occurred between days 4 and 7 could be due to a 
number of growth signals following macrophage efferocytosis of neutrophils, the influx of 
lymphocytes, or cytokine expression from ILC2s around this time point. A study evaluating 
resolution of inflammation in bacterial pneumonia found that alveolar macrophages produced 
hepatocyte growth factor (HGF) upon phagocytosis of inflammatory neutrophils and similarly saw 
an increase in the number of alveolar macrophages between ~2-5 days post-infection followed by 
a decline until day 14 post-infection120. While they did not evaluate macrophage HGF receptor 
62 
 
expression, it is possible that HGF is exerting an autocrine effect as macrophages. In the 
peritoneum and brain, macrophages have been demonstrated to express the receptor, c-met, and 
undergo proliferation in response to HGF121. Given the temporal nature of the proliferation, it is 
feasible that infiltrating T cells could be producing GM-CSF or some other factor that leads to 
macrophage proliferation. 
Notably, there is a steadily increasing population of PKH26-PCL- alveolar macrophages 
that could either be from recruited or unlabeled resident cells, however, the dynamics of this 
population do not mirror those of the PKH26-PCL+ population, thus it’s plausible that these are 
recruited cells. While alveolar macrophages are traditionally defined as being CD11b- in steady 
state, during the acute inflammatory phase, a subpopulation of alveolar macrophages upregulates 
expression of CD11b. This population peaks by day 7 at a 5-fold increase over the naïve lung, and 
subsequently returns to baseline by day 14. Stratification by PKH26-PCL indicates that the 
majority of these cells are from the resident population, but there does exist a much smaller 
population of PKH26-PCL- population with a similar dynamic as the CD64+, CD11c+, SiglecF+, 
PKH26-PCL- alveolar macrophage population.  
Though all of the alveolar macrophage populations evaluated returned to near baseline 
levels, the interstitial macrophage population remained slightly elevated by day 14 after 
undergoing expansion following the administration of elastase through day 4 and subsequently 
declining. Because we only collected data through day 14, it’s unclear if this population remains 
slightly elevated or if it continues to contract. Because interstitial macrophages are seeded from 
peripheral blood monocytes and can replenish alveolar macrophages in cases of depletion, we 
were interested in seeing whether they underwent local proliferation or were of monocyte origin. 
Unfortunately, the labeling of interstitial macrophages was not effective thus this data cannot be 
interpreted with confidence. Interestingly, the PKH26-PCL positive and negative populations 
appear to expand and contract in parallel, thus it’s plausible that they are of the same population. 
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In order to further elucidate the dynamics of interstitial macrophages and PKH26-PCL- alveolar 
macrophages, it is necessary to do a similar experiment where peripheral leukocytes are labeled. 
For instance, bone marrow chimeras where donor hematopoietic cells express green fluorescent 
protein (GFP) and the host resident lung cells are conserved during irradiation by a lung shield 
would allow for tracking of recruited cells into the lung as was performed by Janssen et al. 201125. 
Unfortunately, there are currently no commercially available BALB/cJ transgenic mice that we 
could use for this and while there is a commercially available BALB/cByJ (MHC haplotype matched 
with BALB/cJ) GFP mouse (CByJ.B6-Tg(UBC-GFP)30Scha/J, Stock No. 007076, The Jackson 
Laboratory, Bar Harbor, ME) the strain-dependent phenotypic differences we’ve noted in the 
elastase model likely preclude this as a viable option to study recruited leukocytes.  
Finally, as part of defining the immune cell dynamics following elastase, we looked at 
neutrophils and Ly6C+ monocytes. The dynamics of both populations were as expected with an 
early infiltration peaking on day 2 for neutrophils and day 4 for monocytes. As mentioned 
previously, future experiments should aim to delineate the dynamics and gene expression profiles 
of the two monocyte populations for their role in emphysema. 
Aim 2: Determine if the depletion of resident lung macrophages ameliorates or worsens 
elastase-induced emphysematous changes in the lungs of BALB/cJ mice. 
Based on these data, we decided to deplete lung macrophages between days 3 and 7 
following elastase administration as this was the period leading up to the day 7 expansion and 
phenotypic change in the alveolar macrophage population to a mixed M1/M2 phenotype (previous 
data from the lab, not shown). We found that administering a total of three doses of CLL IT on days 
3, 5, and 7 post-elastase was 85-98% efficacious at depleting alveolar macrophages with the 
highest degree of depletion occurring 24 hours after the third dose. Notably, the depletion was 
maintain at around 92% one week following the third dose of CLL. Interestingly, the 
administration of PLL appeared to cause a degree of alveolar macrophage depletion as E+PLL mice 
64 
 
had almost an order of magnitude fewer alveolar macrophages than elastase-only mice. We 
similarly noted that the dynamics of interstitial macrophages, Ly6C+ monocytes, and neutrophils 
in CLL and PLL treated mice were disparate from the elastase-only mice. This finding is not 
surprising as 1) we are giving a repeated dose of 100 μL of liquid into the lungs which at the very 
least will cause some level of inflammation and likely also introduce bacteria from the upper 
airways into the delicate peripheral airways and 2) the mass depletion of macrophages will induce 
an inflammatory response in itself, confounding our study of the immune environment on 
emphysema severity and progression. For these reasons, the whole lung depletion of macrophages 
is not the ideal technique to study the contribution of macrophages to emphysema. 
In order to evaluate the effect of macrophage depletion on emphysema severity, we 
performed pulmonary function tests to obtain measurements of DFCO, TLC, RV, and quasi-static 
compliance. We found that the DFCO for elastase-treated mice with depleted macrophages was 
significantly lower than mice with intact macrophages, indicating decreased gas-exchange 
capacity of the parenchymal lung tissue. This effect appeared to be independent of liposome 
administration as there was no difference in elastase-only and E+PLL mice. The TLC between 
elastase-treated mice receiving CLL was significantly greater than both E+PLL and elastase-only 
treated mice. Additionally, the TLC of E+PLL mice was greater than that of elastase-only mice. 
Similar results were noted with the quasi-static compliance, however, there was no significant 
difference between E+CLL and E+PLL mice. These data are difficult to interpret because in the PBS 
control-treated mice, a liposome-dependent effect was not noted but a macrophage depletion 
effect was. Perhaps, in the injured elastase-treated lung, the administration of PLL exacerbates the 
inflammatory milieu in the lung leading to increased tissue destruction and thus greater TLC and 
compliance. Additionally, while we did not track the cellular dynamics of PBS+PLL or PBS+CLL 
mice needed to evaluate this finding, in the E+PLL mice, there was a notable decrease in the 
number of alveolar macrophages compared to elastase-only animals. It’s possible that the 
administration of PLL exacerbated the natural early decline in alveolar macrophages in this 
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elastase model system either through liposome phagocytosis-induced macrophage apoptosis or 
migration to the draining lymph nodes.  
In both TLC and quasi-static compliance measurements, there’s a significant difference 
between PBS-treated mice with depleted macrophages and PBS-only or PBS+PLL mice, indicating 
that the depletion of macrophages alone can cause parenchymal destruction. This leads to 
increased compliance and decreased elastance of the lung. Interestingly, this effect is not noted in 
the measure of residual volume as one would expect, however, this is the least sensitive of the 
three measures. The residual volume was significantly increased in elastase-treated mice with 
depleted macrophages compared to E+PLL and elastase-only mice and there was no change in 
residual volume noted in our control mice. Taken together, the pulmonary function results suggest 
that in both naïve (PBS-treated) and emphysematous (elastase-treated) lungs, the depletion of 
macrophages results in decreased gas exchange capacity of the lung parenchyma, increased 
compliance, decreased elastic recoil, and subsequently increased total lung capacity. These effects 



















The hypothesis of this study, that depletion of macrophages prior to their transition to an 
M2/M1 phenotype around day 7 would ameliorate emphysema severity, was not supported by the 
data.  The simplistic interpretation of the results is that depletion of macrophages worsens the 
severity of emphysema.  However, the control arms of the depletion experiments strongly indicate 
that there are serious technical issues with liposome administration in the lungs that have a 
profound influence on the final phenotype. 
At one level, it is not particularly surprising that macrophage depletion resulted in 
enhanced pathology.   Macrophages are instrumental in wound repair and the limiting of 
inflammation in the lung, as discussed in the introduction. To deplete macrophages entirely would 
abrogate not only the dysregulated, destructive repair mechanisms we hypothesize to be 
occurring in our emphysema model but any protective, reparative mechanism they are capable of 
exerting as well. Additionally, the repeated administration of a viscous liquid into the lungs and 
the macrophage depletion events themselves appear to exert an immune modulating effect that 
confounds interpretation of our results. To illustrate the disparate roles that macrophages can 
play in chronic lung disease, one can compare emphysema with idiopathic pulmonary fibrosis 
(IPF). Both disease pathogeneses show a strong association with lung macrophages, however in 
67 
 
IPF there’s excessive extracellular matrix deposition and not enough tissue remodeling122 whereas 
in emphysema, there seems to be a lack of matrix deposition with excessive remodeling89. 
The data from this study indicate that macrophages do play an important role in 
emphysema progression and severity however, the methodology to evaluate their mechanisms of 
action would be better approached from a reprogramming angle rather than full depletion123. 
Previous research in the lab has indicated that an immune environment in the lungs that favors 
Th1/M1 skewing, as seen in the more resistant C57Bl/6J mouse and in mice with decreased 
severity of emphysema following viral infection, may be protective57.  To this end, macrophage-
targeted therapy might be a promising option not only to study the mechanisms of action of 
macrophage but as a therapy to halt emphysema progression in human patients.  
The macrophage phenotype can be altered in a number of ways including, but not limited 
to, the in situ administration of IRF/STAT signaling pathway agonists and inhibitors, growth 
factors, and the adoptive transfer of macrophages phenotypically skewed in vitro124. The effects of 
adoptively transferring macrophages polarized in vitro or through genetic manipulation of a 
known defective gene to rodent models of disease has recently proven successful in rescuing 
spinal cord injury in rats125, endotoxemia in mice126, and hereditary pulmonary alveolar 
proteinosis (herPAP) in mice127. Importantly, macrophage therapy appears to have the capacity 
for a long lasting effect as demonstrated in the transplantation of macrophage progenitors to treat 
a murine model of the hereditary form of pulmonary alveolar proteinosis (PAP), a lung disease 
caused by mutations in the gene encoding GM-CSF. With a single treatment of macrophage 
progenitors, the cells engrafted and differentiated into functional macrophages capable of 
significantly ameliorating PAP symptoms for at least 9 months128. Additionally, the direct 
administration of polarizing stimuli including interferon (IFN)-γ129 (towards M1) and IL-4130 
(towards M2) has demonstrated improved resolution of infection and inflammation, respectively. 
Notably, this blanket administration of stimuli that act on a variety of cells could have negative off-
68 
 
target effects, thus a focused intervention specific to macrophages would be ideal. Indeed, the use 
of a chemically modified viral nanoparticles to deliver polarizing agents to macrophages in vitro 
was recently demonstrated not only to specifically target macrophages but to be sequestered 
differentially by M1/M2 phenotype131.  
Emphysema is a complex immunological disease that involves multiple cell types, effector 
molecules, genes, and environmental factors. The work in this thesis gives a glimpse into the 
complexities of myeloid cell dynamics following the onset of elastase-induced lung damage and 
contributes to our appreciation for the role of the lung macrophage in the progressive alveolar 
destruction seen in our model. Future studies incorporating monocyte tracking, macrophage 
reprogramming, and gene expression analysis will help further delineate the dynamics and role of 
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